MedTrace Logo

LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects

NCT04865653 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-02-14

No results posted yet for this study

Summary

Lysergic acid diethylamide (LSD) is used as recreational substance and as a research substance to study the mind. Recreationally, LSD is typically used in the form of "blotters" containing LSD tartrate. In research, both LSD base (LSD alone) or LSD salt in the form of LSD tartrate are used. The oral bioavailability of LSD is not known and LSD alone and LSD as salt have never been directly compared regarding their equivalence of plasma concentrations and effects. Because different forms of LSD are used in research it is important to know their difference or equivalence for correct dosing of LSD. The present study will compare equivalent doses of LSD base in ethanol orally, LSD tartrate in water administered orally, LSD base in an orodispersible film administered orally and LSD tartrate in water administered intravenously, as well as a placebo using a double-blind, randomized, counterballanced cross-over design in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

Lysergic Acid Diethylamide Base oral drinking solution

A moderate dose of 0.1 mg LSD will be administered.

DRUG

Lysergic Acid Diethylamide Base solid orodispersible film

A moderate dose of 0.1 mg LSD will be administered.

DRUG

Lysergic Acid Diethylamide Tartrate oral drinking solution

A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).

DRUG

Lysergic Acid Diethylamide Tartrate intravenous administration

A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).

OTHER

LSD Placebo

Placebo for each formulation containing only the solvent or gel but no LSD.

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias E Liechti, MD · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-17
Primary Completion
2023-10-11
Completion
2023-10-11

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04865653 on ClinicalTrials.gov